CD274 and cancer: Due to their significant success in clinical trials, several anti-PD-1 mAbs, including nivolumab, pembrolizumab, and others, as well as anti-PD-L1 mAbs such as atezolizumab, durvalumab, and avelumab, have been approved for the treatment of different cancers [20].